Mallinckrodt PLC has received $1.84 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 11 Financial Advisor in the Stock Trading Firms. Among 11 Analysts, Bottom line EPS Estimate for the current quarter is $1.7 while the top line estimate is $1.94 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -12.05%.
Mallinckrodt PLC reported better than expected with a surprise EPS of 3.03% or $0.06 during its most recent quarterly earnings. The Actual EPS was $2.04 compared to the Estimated EPS of $1.98.
Mallinckrodt PLC has a Price to Earnings ratio of 5.57 for the trailing twelve month period. The price to book ratio of the company for the most recent quarter is 0.95. For the Most Recent Fiscal Year, Mallinckrodt PLC has a price to cash ratio of 9.95. For the Trailing twelve month period, company showed a Net Profit Margin of 17.44% and Return on Equity of the stock is 17.92%.
In the last quarter, Mallinckrodt PLC reported Annual Earnings of $2.04. Based on the filings, last years Annual Earnings was, $7.85. In the last Quarter, MNK reported a surprise Earnings per Share of 3.03% . The consensus estimate for current quarter is $1.84 and for the current fiscal year, the estimate is $7.71. For the Next fiscal year, the estimate is $7.67 based on the consensus.
Mallinckrodt plc (NYSE:MNK) : On Tuesday heightened volatility was witnessed in Mallinckrodt plc (NYSE:MNK) which led to swings in the share price. The stock opened for trading at $45.96 and hit $48.77 on the upside , eventually ending the session at $48.73, with a gain of 4.91% or 2.28 points. The heightened volatility saw the trading volume jump to 1,595,231 shares. The 52-week high of the share price is $85.83 and the company has a market cap of $5,106 million. The 52-week low of the share price is at $42.6701 .
Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The companys Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.